EGFR and pancreatic ductal adenocarcinoma: KRAS Q61H, the most prevalent mutation occurring at codon 61 of KRAS3, has been found in about 5% of pancreatic ductal adenocarcinoma (PDAC) patients32,33 and has also been reported as a mechanism of acquired anti-epidermal growth factor receptor (EGFR) drug resistance in both lung and colorectal cancers34–36.